Support for evidence-based projects that focus on at least 1 community identified ‘focus population’ in the NSW Cancer Plan, have the potential to be embedded and scaled up in the health system, and are sustainable past the funding period.
Key information
- Status: Closed
- Grant amount: $800,000
- Application opened: 19 June 2024
- Application closed: 14 August 2024, 1:00 pm
Program objective
The Accelerated Research Implementation Grants aim to support high achieving research teams who have the ability and capacity to:
- Rapidly implement current research into clinical practice that will improve cancer care or cancer outcomes within three years
- Demonstrate a logical pipeline of research implementation across the three years of funding
- Demonstrate a scalability plan to roll out initiatives to multiple sites within NSW
- Demonstrate a sustainability plan to ensure continued application of the research implementation past the funding period
- Demonstrate an evaluation approach that includes both process measures and outcome measures
- Assemble a team with the relevant skills and a track record of working together for the entire program which will, by definition, be multi-disciplinary and multi-institutional. This will need to include clinical partners that span metropolitan and non-metropolitan health care settings.
This program is funded and administered by Cancer Institute NSW.
Eligibility
Who can apply
Each ARIG application will have one named Chief Investigator, with a minimum of 0.2 FTE towards the activities of the program. The Chief Investigator must be employed at an institution within NSW for the duration of the grant.
Who can’t apply
Researchers outside of NSW.
Types of projects funded under this grant
The ARIG targets the T2 and T3 stages of translational research. It aims to focus on translating new clinical science and knowledge into routine clinical practice and health decision making, and the disseminating and implementing research for system-wide change.
Examples of projects may include:
- Translation of new clinically proven knowledge of disease processes, diagnostic or treatment techniques into routine clinical practice and health decision making
- Application of information and insights derived from clinical and population health research to the provision of health services
- Moving evidence-based guidelines into health practice, through delivery and dissemination
- Practice-based research, where the evidence from clinical trials is translated into guidelines for patients seen routinely in practice.
What can’t you apply for
Funds awarded cannot be used for any purposes associated with basic (i.e., desk, stationery, phone) or overhead infrastructure costs (i.e., institutional overheads of administrative levies). Funds should not be used to support research conducted outside of NSW.
Most recent recipients
What your application needs to include
Applications must be submitted via the Grants Management System (GMS).
Applicants must include the following in their Cancer Institute NSW Accelerated Research Implementation application:
- Application Form (completed in GMS)
- Program Logic Model
- Risk Management Plan
- Endorsement letter
- Relevant support letters
- NSW Aboriginal Health Impact Statement (if applicable).
Prepare your application with this checklist
- Application Form (completed in GMS)
- Program Logic Model
- Risk Management Plan
- Endorsement letter
- Relevant support letters
- NSW Aboriginal Health Impact Statement (if applicable).
Address the eligibility criteria
Each ARIG application will have one named Chief Investigator, with a minimum of 0.2 FTE towards the activities of the program. The Chief Investigator must be employed at an institution within NSW for the duration of the grant.
Address the assessment criteria
- Significance (20%)
The primary aim of the ARIG must have appropriate emphasis on at least one community identified as a ‘focus population’ in the NSW Cancer Plan.
- Aboriginal communities
- Multicultural communities
- People from lower socioeconomic backgrounds
- Regional, rural and remote communities
- Older people
- Sexuality and gender diverse people (lesbian, gay, bisexual, transgender, intersex and queer people, known as LGBTIQ+ communities)
- People with a mental health condition
- People who are engaged with the justice system.
The significance of the project should be demonstrated by:
- Addressing a major evidence-practice gap of critical importance in the focus population
- Having a high potential to increase the survival and/or quality of life of people with cancer through the translation of research. This could include, but is not limited to:
- Implementing new best clinical practice guidelines or policies
- Improving data collection and analysis processes
- Training critical staff to contribute to the provision of best-practice cancer treatment to drive better outcomes
- A feasible research implementation plan (rationale, design, methodology) with anticipated outcomes to accomplish the aims of the grant
- Consumer engagement throughout the entirety of the implementation program.
- Scalability (20%)
The applicants must demonstrate a scalability plan to roll out initiatives to multiple sites within NSW. Considerations include:
- Pathways for scaling up research findings across NSW
- Likely level of adoption or uptake of project
- Likely required timeframes required to achieve desired results.
- Sustainability (20%)
The applicants must demonstrate that the research team has a plan after the completion of the grant funding. Considerations include:
- Evidence of established strategic partnerships and stakeholder engagement strategies to ensure successful translation
- Ensuring equitable access to the intervention.
- Evaluation and Outputs (20%)
The applicant must demonstrate that the research team has a plan for the evaluation of the implementation program and the resulting outcomes. Considerations include:
- A clear process for monitoring the progress of the implementation program, including achievable key milestones and outcome indicators that can be delivered during the grant
- The economic impact on the focus area
- The potential to impact on health service improvements
- The anticipated ability to leverage future funding.
- Team Track Record (20%)
The named Investigators as individuals and as a diverse research team, should demonstrate:
- A track record in managing and successfully implementing translational research
- A high degree of established collaborations amongst team members with reference to the length of collaboration and achievements
- A clear plan on how the research team will promote and sustain a collaborative approach for the duration of the grant funding
- Capability to undertake the proposed implementation program in the grant timeframe and to continue.
After the application is submitted
The applications will be assessed and both successful and unsuccessful applicants will be notified.
The Cancer Institute NSW will consider all recommendations for funding by the Grants Review Committee and the Chief Executive will approve funding for the grants to be awarded.